ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1
K Wang, X Qiu, Z Zhang, H Xu, Y Tan, R Su… - Cell Communication and …, 2023 - Springer
Background Sorafenib resistance greatly reduces the efficacy of treatments in advanced
hepatocellular carcinoma (HCC) patients, but the underlying mechanisms are not thoroughly …
hepatocellular carcinoma (HCC) patients, but the underlying mechanisms are not thoroughly …
Activation of AMP‐activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib
N Ishijima, K Kanki, H Shimizu, G Shiota - Cancer science, 2015 - Wiley Online Library
To improve the outcome of cancer chemotherapy, strategies to enhance the efficacy of
anticancer drugs are required. Sorafenib is the only drug to prolong overall survival of the …
anticancer drugs are required. Sorafenib is the only drug to prolong overall survival of the …
[PDF][PDF] Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
P JC, A LC - 2011 - Citeseer
Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
Y Haga, T Kanda, M Nakamura, S Nakamoto… - PLoS …, 2017 - journals.plos.org
Background Despite recent advances in treatment strategies, it is still difficult to cure patients
with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase …
with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase …
[HTML][HTML] PAK3 promotes the metastasis of hepatocellular carcinoma by regulating EMT process
Z Gao, M Zhong, Z Ye, Z Wu, Y Xiong, J Ma… - Journal of …, 2022 - ncbi.nlm.nih.gov
Purpose: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors.
The malignant biological behavior of HCC is closely related to epithelial-mesenchymal …
The malignant biological behavior of HCC is closely related to epithelial-mesenchymal …
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
KF Chen, HL Chen, WT Tai, WC Feng, CH Hsu… - … of Pharmacology and …, 2011 - ASPET
Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …
[HTML][HTML] LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
Y Ma, R Xu, X Liu, Y Zhang, L Song, S Cai… - … journal of medical …, 2021 - ncbi.nlm.nih.gov
Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma;
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …
P21-Activated Protein Kinase Is Overexpressed in Hepatocellular Carcinoma and Enhances Cancer Metastasis Involving c-Jun NH2-Terminal Kinase Activation and …
YP Ching, VYL Leong, MF Lee, HT Xu, DY Jin, IOL Ng - Cancer research, 2007 - AACR
Hepatocellular carcinoma (HCC) is one of the major malignancies in the world. The
prognosis of HCC is poor, due to frequent intrahepatic metastasis and tumor recurrence …
prognosis of HCC is poor, due to frequent intrahepatic metastasis and tumor recurrence …
[HTML][HTML] Down-regulation of TGF-β expression sensitizes the resistance of hepatocellular carcinoma cells to sorafenib
D Kang, Z Han, GH Oh, Y Joo, HJ Choi… - Yonsei medical …, 2017 - ncbi.nlm.nih.gov
Purpose Sorafenib, a multikinase inhibitor, is the standard therapy for patients with
advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the …
advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the …
[HTML][HTML] AKR1B10 inhibitor epalrestat facilitates sorafenib-induced apoptosis and autophagy via targeting the mTOR pathway in hepatocellular carcinoma
N Geng, Y Jin, Y Li, S Zhu, H Bai - International Journal of Medical …, 2020 - ncbi.nlm.nih.gov
Sorafenib is the standard systemic treatment for advanced hepatocellular carcinoma (HCC),
and improving its therapeutic effects is crucial for addressing cancer aggression. We …
and improving its therapeutic effects is crucial for addressing cancer aggression. We …